Trial · NCT03211247
Adverse events720
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 720
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Application Site Erythema | General disorders | Part B Viaskin Peanut 250 mcg | 239 | 244 | 2,182 |
| other | Application Site Erythema | General disorders | Part B Placebo | 107 | 118 | 760 |
| other | Application Site Erythema | General disorders | Part A Viaskin Peanut 250 mcg | 18 | 21 | 21 |
| other | Application Site Erythema | General disorders | Part A Viaskin Peanut 100 mcg | 14 | 20 | 15 |
| other | Application Site Erythema | General disorders | Part A Placebo | 6 | 10 | 13 |
| other | Application Site Pruritus | General disorders | Part B Viaskin Peanut 250 mcg | 231 | 244 | 2,925 |
| other | Application Site Pruritus | General disorders | Part B Placebo | 72 | 118 | 523 |
| other | Application Site Pruritus | General disorders | Part A Viaskin Peanut 250 mcg | 13 | 21 | 15 |
| other | Application Site Pruritus | General disorders | Part A Viaskin Peanut 100 mcg | 11 | 20 | 29 |
| other | Application Site Pruritus | General disorders | Part A Placebo | 1 | 10 | 2 |
| other | Application Site Swelling | General disorders | Part B Viaskin Peanut 250 mcg | 177 | 244 | 2,044 |
| other | Application Site Swelling | General disorders | Part B Placebo | 46 | 118 | 278 |
| other | Application Site Swelling | General disorders | Part A Viaskin Peanut 250 mcg | 7 | 21 | 15 |
| other | Application Site Swelling | General disorders | Part A Viaskin Peanut 100 mcg | 2 | 20 | 3 |
| other | Application Site Swelling | General disorders | Part A Placebo | 2 | 10 | 2 |
| other | Pyrexia | General disorders | Part B Viaskin Peanut 250 mcg | 84 | 244 | 150 |
| other | Pyrexia | General disorders | Part B Placebo | 50 | 118 | 83 |
| other | Pyrexia | General disorders | Part A Viaskin Peanut 250 mcg | 5 | 21 | 8 |
| other | Pyrexia | General disorders | Part A Viaskin Peanut 100 mcg | 6 | 20 | 11 |
| other | Pyrexia | General disorders | Part A Placebo | 2 | 10 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03211247/events